Keyword: EuroBiotech Report
MorphoSys has $500 million-plus to crash the CAR-T party with a drug it thinks provides safer, more durable efficacy without the cost or complexity.
In this week's EuroBiotech Report, Novartis nabs Amgen CMO, Inventiva gears up for NASH phase 3, Lysogene delays trial start and more.
In our EuroBiotech roundup this week, Scancell raises cash for cancer trial, Autolus posts CAR-T data and Adocia starts diabetes study.
Tsai took up the same position at Amgen 11 months ago but had his head turned by the digitally enabled pipeline Narasimhan is building at Novartis.
A manufacturing delay has pushed back the start of Lysogene’s pivotal Sanfilippo syndrome trial into the second half of the year.
The financing will see Inventiva through a period in which it will drop data from a phase 2b NASH trial and a two-year carcinogenicity study.
In this week's EuroBiotech Report, Alexion pens $855 million Wilson buyout, Novartis sells failed cancer drug, Novo inks sickle cell deal and more.
In our EuroBiotech roundup this week, GlaxoSmithKline sells its gene therapy unit, Genfit hits a trial milestone and Verona's CMO quits.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
The takeover furthers Alexion’s pipeline rebuild by giving it control of WTX101, a phase 3 treatment for the rare genetic disorder Wilson disease.